Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Bladder Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 29 articles: HTML format

Single Articles

November 2025
1. BIAN X, Yang T, Yin H, Hu B, et al
   Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial.
   J Clin Oncol. 2025;43:3505-3515.
   PubMed     Abstract available
   
   
   October 2025
2. BANDARI J, Messing EM
   Single-Arm Pivotal Studies in Bacillus Calmette-Guerin-Unresponsive Non-Muscle-Invasive Bladder Cancer.
   J Clin Oncol. 2025 Oct 21:JCO2501893. doi: 10.1200/JCO-25-01893.
   PubMed    
   
   
   September 2025
3. NECCHI A, Galsky MD, Dizman N, Aggen DH, et al
   End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
   J Clin Oncol. 2025 Sep 11:JCO2501608. doi: 10.1200/JCO-25-01608.
   PubMed     Abstract available
   
   
   
4. DANESHMAND S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, et al
   Erratum: TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
   J Clin Oncol. 2025 Sep 9:JCO2502053. doi: 10.1200/JCO-25-02053.
   PubMed    
   
   
   August 2025
5. GALSKY MD, Ballas L, Kamat AM
   Muscle-Invasive Bladder Cancer: A Watershed Moment.
   J Clin Oncol. 2025 Aug 5:JCO2500718. doi: 10.1200/JCO-25-00718.
   PubMed     Abstract available
   
   
   July 2025
6. DANESHMAND S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, et al
   TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
   J Clin Oncol. 2025 Jul 30:101200JCO2501651. doi: 10.1200/JCO-25-01651.
   PubMed     Abstract available
   
   
   April 2025
7. BRYAN RT, Liu W, Pirrie SJ, Amir R, et al
   Errata: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
   J Clin Oncol. 2025 Apr 23:JCO2500779. doi: 10.1200/JCO-25-00779.
   PubMed    
   
   
   February 2025
8. KAMAT AM, Frankel P
   Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer?
   J Clin Oncol. 2025 Feb 5:JCO2402482. doi: 10.1200/JCO-24-02482.
   PubMed    
   
   
   January 2025
9. BRYAN RT, Liu W, Pirrie SJ, Amir R, et al
   Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
   J Clin Oncol. 2025 Jan 14:JCO2302398. doi: 10.1200/JCO.23.02398.
   PubMed     Abstract available
   
   
   
10. GALSKY MD, Witjes JA, Gschwend JE, Milowsky MI, et al
    Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
    J Clin Oncol. 2025;43:15-21.
    PubMed     Abstract available
    
    
    December 2024
11. GEYNISMAN DM, Abbosh PH, Ross E, Zibelman MR, et al
    Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
    J Clin Oncol. 2024 Dec 16:JCO2401214. doi: 10.1200/JCO-24-01214.
    PubMed     Abstract available
    
    
    October 2024
12. MARCQ G, Kool R, Dragomir A, Kulkarni GS, et al
    Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis.
    J Clin Oncol. 2024 Oct 3:JCO2302718. doi: 10.1200/JCO.23.02718.
    PubMed     Abstract available
    
    
    September 2024
13. MERCINELLI C, Moschini M, Cigliola A, Mattorre B, et al
    First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2024 Sep 6:JCO2400576. doi: 10.1200/JCO.24.00576.
    PubMed     Abstract available
    
    
    
14. DAHL DM, Rodgers JP, Shipley WU, Michaelson MD, et al
    Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
    J Clin Oncol. 2024 Sep 3:JCO2302510. doi: 10.1200/JCO.23.02510.
    PubMed     Abstract available
    
    
    July 2024
15. KLUMPER N, Tran NK, Zschabitz S, Hahn O, et al
    NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
    J Clin Oncol. 2024;42:2446-2455.
    PubMed     Abstract available
    
    
    April 2024
16. SHENG X, Wang L, He Z, Shi Y, et al
    Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
    J Clin Oncol. 2024;42:1391-1402.
    PubMed     Abstract available
    
    
    December 2023
17. HE W, Zeng S, Xu C
    Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Dec 5:JCO2301920. doi: 10.1200/JCO.23.01920.
    PubMed    
    
    
    November 2023
18. CATHOMAS R, Rothschild SI, Hayoz S, Bubendorf L, et al
    Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
    J Clin Oncol. 2023;41:5131-5139.
    PubMed     Abstract available
    
    
    October 2023
19. KAMAT AM, Apolo AB, Babjuk M, Bivalacqua TJ, et al
    Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
    J Clin Oncol. 2023 Oct 4:JCO2300307. doi: 10.1200/JCO.23.00307.
    PubMed     Abstract available
    
    
    September 2023
20. SIEFKER-RADTKE AO, Cauley D, Alhalabi O
    Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:4084-4086.
    PubMed    
    
    
    August 2023
21. VON DER MAASE H, Hansen SW, Roberts JT, Dogliotti L, et al
    Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
    J Clin Oncol. 2023;41:3881-3890.
    PubMed     Abstract available
    
    
    
22. SMALL EJ
    Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
    J Clin Oncol. 2023;41:3879-3880.
    PubMed    
    
    
    
23. STEIN JP, Lieskovsky G, Cote R, Groshen S, et al
    Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients.
    J Clin Oncol. 2023;41:3772-3781.
    PubMed     Abstract available
    
    
    
24. 
    JCO Flashback: Long-Term Outcomes of Radical Cystectomy in Patients With Invasive Bladder Cancer (2001).
    J Clin Oncol. 2023;41:3771.
    PubMed    
    
    
    
25. BOSL GJ
    Flashback Foreword: Radical Cystectomy in the Treatment of Bladder Cancer.
    J Clin Oncol. 2023;41:3769-3770.
    PubMed    
    
    
    July 2023
26. SWINTON M, Mariam NBG, Tan JL, Murphy K, et al
    Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Jul 21:JCO2300725. doi: 10.1200/JCO.23.00725.
    PubMed     Abstract available
    
    
    
27. POWLES T, Park SH, Caserta C, Valderrama BP, et al
    Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up.
    J Clin Oncol. 2023;41:3486-3492.
    PubMed     Abstract available
    
    
    June 2023
28. SARFATY M, Golkaram M, Funt SA, Al-Ahmadie H, et al
    Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
    J Clin Oncol. 2023;41:3225-3235.
    PubMed     Abstract available
    
    
    March 2023
29. COLEMAN JA, Yip W, Wong NC, Sjoberg DD, et al
    Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
    J Clin Oncol. 2023;41:1618-1625.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.